The Week

BioNTech (BNTX) traded near the $97 mark this week, with the latest quote at $96.900 after touching a post-market high of $98.500. The weekly close and percentage change are not available in the returned data, so no weekly return can be calculated here. Intraday ranges stayed within $96.216 to $97.995, pointing to a choppy week rather than a sustained directional move.

Key Events

The main theme this week was capacity reduction alongside repeated insider selling. On Monday, BioNTech said it would shutter production sites in Germany and Singapore after failing to find buyers, putting its post-COVID manufacturing footprint back in focus. CEO Uğur Şahin then disclosed disposals of roughly $6.09m, $6.48m and $3.30m in common shares across Tuesday, Thursday and Saturday. Media coverage during the week compared BioNTech with Moderna on mRNA cancer upside, and asked whether vaccine approvals could shift the bull case. On the industry side, Pfizer and Moderna failed to get Bayer’s US mRNA patent lawsuit dismissed, keeping patent risk in the background.

Analyst Ratings

Among 20 brokers covering BioNTech, 13 rate it buy, 1 overweight, 5 hold and 1 underweight, with no sell or no-opinion calls; the consensus rating is buy. The consensus target is about $116.99, which sits roughly 20.7% above the latest price of $96.90. Individual targets range from $73.923 to $141.028, a spread of nearly $67, showing wide disagreement over the vaccine and oncology pipeline. The stock ranks 23rd out of 507 names in the biotech industry rating table.

The Week Ahead

Next week brings a busy macro calendar: S&P Global services PMI final and ISM non-manufacturing PMI on Monday, trade balance data on Tuesday, and EIA crude inventory figures on Wednesday. On the company side, the next results are fiscal Q3 2026 earnings, with estimates at $0.8836 EPS and $1.206bn revenue, listed for 3 November. The announced site closures in Germany and Singapore should also show up in future reporting through headcount, impairment and related cost items.

In Short

This week sets capacity cuts and repeated CEO share sales against a consensus buy rating and a target about 20.7% above spot. Valuation is negative on earnings, with PB near 1.2x, while the latest session showed no large-lot net inflow. The next checkpoints are Q3 earnings and any detail on how the site shutdowns reshape the cost base and, in turn, broker target ranges.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.